达菲林用于儿童中枢性性早熟的的疗效观察.docVIP

达菲林用于儿童中枢性性早熟的的疗效观察 　　【摘要】目的：观察注射用达菲林治疗儿童中枢性性早熟的疗效及安全性。方法：选取我院2012年5月至2014年12月确诊为中枢性性早熟的患儿30例，随机分为观察组和对照组，其中对照组15例，采用促性腺激素释放激素治疗；观察组15例，采用达菲林贮库型悬浮液治疗，观察并比较两组的疗效和并发症发生情况。结果：观察组治疗有效率（933%）明显好于对照组（733%），P005；各项指标治疗后均低于治疗前，组间差异有统计学意义，P005；观察组不良反应发生率为667%对照组为2667%，P005。结论：达菲林（Diphereline）治疗儿童中枢性性早熟疗效可靠，不良反应少，值得临床推广。 　　【关键词】中枢性性早熟；达菲林；疗效 　　The curative effect of diphereline in the treatment of central precocious pubertyFANG Qin， LI Jie， ZHANG Haiyan， JIANG Yan， TAO Ye. Department of Pediatrics， Kunshan First People’s Hospital Affiliated to Jiangsu University， Suzhou 215300， Jiangsu， China 　　【Abstract】Objectives： To observe the curative effect and safety of diphereline in the treatment of central precocious puberty. Methods： 30 children diagnosed as central precocious puberty in our hospital from May 2012 to December 2014 were selected and randomly divided into observation group and control group， 15 children in each group. The observation group received America Abbott company production of diphereline for treatment while the control group received gonadotropin releasing hormone for treatment. The efficacy and incidence of complications in the two groups were compared. Results： The treatment efficiency in the observation group （93.3%） was significantly better than the control group （73.3%， P005）； all the indexes after treatment were lower than those before treatment， with statistically significant differences （P005）； the incidence of adverse reactions in the observation group and control group was 6.67% and 26.67% respectively， P005. Conclusions： Diphereline is reliable in the treatment of central precocious puberty， with less adverse reaction， which is worth clinical promotion. 　　【Key words】Central precocious puberty； Leuprorelin acetate suspension； Curative effect 　　【中图分类号】R167【文献标志码】A 　　性早熟是一种发育异常性疾病，患儿常出现性发育提前，女童在8岁前、男童在9岁前呈现第二性征[1，2]。中枢性性早熟（central precocious puberty，CPP）又称真性性早熟，是性早熟中最重要的一种，由于各种原因导致下丘脑-垂体-性腺轴提前激活，使促性腺激素释放激素 （GnRH） 释放增多，最终出现性腺发育提前和第二性征提前，并伴随发生内